Characterizing the Drug Development Pipeline for Precision Medicines

Amitabh Chandra, Craig Garthwaite, Ariel Dora Stern

NBER Working Paper No. 24026
Issued in November 2017
NBER Program(s):Health Care, Industrial Organization, Public Economics, Productivity, Innovation, and Entrepreneurship

Precision medicines – therapies that rely on genetic, epigenetic, and protein biomarkers – create a better match between individuals with specific disease subtypes and medications that are more effective for those patients. These treatments are expected to be both more effective and more expensive than conventional therapies, implying that their introduction is likely to have a meaningful effect on health care spending patterns. In addition, precision medicines can change the expected profitability of therapies both by allowing more sophisticated pricing systems and potentially decreasing the costs of drug development through shorter and more focused trials. As a result, this could change the types of products that can be profitably brought to market. To better understand the landscape of precision medicines, we use a comprehensive database of over 130,000 global clinical trials, over the past two decades. We identify clinical trials for likely precision medicines (LPMs) as those that use one or more relevant biomarkers. We then further segment trials based on the nature of the biomarker(s) used and other trial features with economic implications. Given potential changes in the incentives for bringing products to market, we also examine the relative importance of public agencies such as the National Institutes of Health (NIH) and different types of private firms in developing precision medicines.

You may purchase this paper on-line in .pdf format from ($5) for electronic delivery.

Access to NBER Papers

You are eligible for a free download if you are a subscriber, a corporate associate of the NBER, a journalist, an employee of the U.S. federal government with a ".GOV" domain name, or a resident of nearly any developing country or transition economy.

If you usually get free papers at work/university but do not at home, you can either connect to your work VPN or proxy (if any) or elect to have a link to the paper emailed to your work email address below. The email address must be connected to a subscribing college, university, or other subscribing institution. Gmail and other free email addresses will not have access.


The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w24026

Forthcoming: Characterizing the Drug Development Pipeline for Precision Medicines, Amitabh Chandra, Craig Garthwaite, Ariel Dora Stern. in Economic Dimensions of Personalized and Precision Medicine, Berndt, Goldman, and Rowe. 2018

Users who downloaded this paper also downloaded* these:
Berndt and Trusheim w24020 The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory
Bailey, Cole, Henderson, and Massey w24019 How Well Do Automated Methods Perform in Historical Samples? Evidence from New Ground Truth
Park, Basu, Coe, and Khalil w24038 Service-level Selection: Strategic Risk Selection in Medicare Advantage in Response to Risk Adjustment
Howard, Hockenberry, and David w24054 Personalized Medicine When Physicians Induce Demand
Chandra and Staiger w24035 Identifying Sources of Inefficiency in Health Care
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us